$7.400
-0.529 (-7.15%)At close
SENS News
SENS Events
Beta Bionics Partners with Senseonics for New System Launch
Beta Bionics (BBNX) announced a partnership to integrate the iLet Bionic Pancreas and mint automated insulin delivery systems with Senseonics' (SENS) Eversense 365 continuous glucose monitoring system. Commercial launch of the integrated iLet and Eversense 365 system is expected in the fourth quarter of 2026, at which time Beta Bionics expects iLet to support the most CGM manufacturer options of any AID system.
Senseonics Partners with Beta Bionics to Develop Automated Insulin Delivery System
Senseonics (SENS) announced a partnership with Beta Bionics (BBNX). The companies are collaborating to integrate Eversense 365 CGM with Beta Bionics' iLet Bionic Pancreas automated insulin delivery system designed to simplify diabetes management.
Company Raises FY26 Gross Margin Guidance to 58%-61%
Consensus $62.18M. Raises FY26 gross margin guidance to a range of 58%-61% from 55%-58%. "Given our momentum, we're raising our full-year revenue and margin guidance. We're not just growing the business - we're redefining what a CGM can be," said CEO Tim Goodnow.
Senseonics Reports Q2 Revenue of $14.5M, Exceeds Expectations
Reports Q2 revenue $14.5M, consensus $12.91M. U.S. revenue grew more than 150% year-over-year to $12.6M. "This was the strongest quarter in Senseonics' history, achieving record revenue and expanded margins, while integrating European commercial operations, building Eon Care, and advancing our Gemini and Freedom development programs," said CEO Tim Goodnow.
Senseonics Reports Q1 Revenue of $9.34M
Reports Q1 revenue $9.34M, consensus $9.83M. Tim Goodnow, President and Chief Executive Officer of Senseonics, said, "This was our first quarter as a fully-integrated commercial organization in the U.S., following the successful transition of the U.S. Eversense Sales and Marketing team to Senseonics. However, this wasn't just a quarter of important strategic progress, it was a strong quarter of commercial delivery, with both revenue and gross margins exceeding our expectations. We have now secured over $100 million in equity and debt financing to continue to fund our ongoing global launch of Eversense 365 and support the continued development of our pipeline, which includes the Gemini and Freedom systems. I'm proud of the team's ability to both adapt and deliver during a crucial evolution of our business, which is now end-to-end, gaining momentum and moving forward more ambitiously."
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.